GSK’s Viehbacher To Head Sanofi-Aventis
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis gains a new leader with the departure of North American Pharma Head Viehbacher from GlaxoSmithKline.
You may also be interested in...
Sanofi’s Message On Emerging Markets? Catch Us If You Can
Three years ago Sanofi didn’t know it was number one in emerging markets. Now the French pharma can’t talk enough about emerging markets – so what happened?
Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Sanofi Aventis reported second quarter net sales up 6.5 percent at constant exchange rates, despite the early impact of generic competition in Europe on the heart drug Plavix (clopidogrel), anti-hypertensive Avapro (irbesartan), and cancer drug Eloxatin (oxaliplatin)
Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Sanofi Aventis reported second quarter net sales up 6.5 percent at constant exchange rates, despite the early impact of generic competition in Europe on the heart drug Plavix (clopidogrel), anti-hypertensive Avapro (irbesartan), and cancer drug Eloxatin (oxaliplatin)